어류용 구충제 시장 : 시장 기회, 성장 요인, 산업 동향 분석 및 예측(2026-2035년)

The Global Fish Anthelmintics Drugs Market was valued at USD 256 million in 2025 and is estimated to grow at a CAGR of 5.3% to reach USD 430.5 million by 2035.

Market growth is driven by the rapid expansion of aquaculture, the increasing prevalence of parasitic infestations in farmed fish, and rising demand for high-quality seafood. Anthelmintic drugs play a critical role in controlling internal parasitic worms such as nematodes, cestodes, and trematodes that negatively impact fish health, growth rates, and survival. As aquaculture operations intensify to meet global protein demand, effective parasite management has become essential to minimize economic losses and ensure sustainable fish farming practices. The growing emphasis on fish health management and biosecurity has significantly increased the adoption of fish anthelmintics across commercial aquaculture facilities. Parasitic infections not only reduce feed efficiency and weight gain but also increase mortality rates, directly affecting farm profitability. As a result, aquaculture producers are increasingly investing in preventive and therapeutic drug solutions to maintain stock health. Regulatory bodies in several countries are also encouraging the controlled use of veterinary pharmaceuticals to improve food safety standards, further supporting market growth. Additionally, advancements in formulation technologies have led to more targeted, residue-controlled, and environmentally safer anthelmintic drugs, improving treatment outcomes and compliance with regulatory norms.

Based on drug class, the market is segmented into benzimidazoles, macrocyclic lactones, praziquantel, and others, with the benzimidazoles segment generating USD 65.5 million in 2025. Benzimidazoles are widely preferred due to their broad-spectrum efficacy against gastrointestinal nematodes and trematodes, cost-effectiveness, and ease of administration through medicated feed. These drugs interfere with parasite metabolism and energy production, leading to effective parasite elimination while maintaining acceptable safety margins for fish. Their extensive use in both freshwater and marine aquaculture systems has solidified their leading market position.

The B2B segment held 49.6% share in 2025, driven by strong demand from commercial aquaculture farms, hatcheries, integrated fish producers, and large-scale seafood exporters. These buyers prioritize reliable, high-efficacy anthelmintic solutions to manage parasite outbreaks in high-density farming environments where infection risks are elevated. B2B customers typically procure fish anthelmintics in bulk through veterinary suppliers, aquaculture input distributors, and direct manufacturer contracts, ensuring consistent supply and cost efficiency

Asia Pacific Fish Anthelmintics Drugs Market reached USD 193 million in 2025, supported by the region's large-scale aquaculture production, growing seafood consumption, and expanding commercial fish farming operations. Countries such as China, India, Vietnam, and Indonesia are major contributors, owing to their extensive inland and coastal aquaculture activities. The increasing adoption of modern fish health management practices, combined with government initiatives to improve aquaculture productivity and disease control, has significantly boosted the use of veterinary drugs in the region.

Key players operating in the Global Fish Anthelmintics Drugs Market include Zoetis Inc., Elanco Animal Health, Merck & Co. (MSD Animal Health), Virbac, Vetoquinol, Ceva Sante Animale, Huvepharma, and Phibro Animal Health Corporation. Companies operating in the Fish Anthelmintics Drugs Market are focusing on product innovation, strategic partnerships, and geographic expansion to strengthen their market presence. Leading players are investing heavily in research and development to introduce advanced formulations with improved efficacy, reduced environmental impact, and lower drug residue levels to meet stringent regulatory standards. Collaborations with aquaculture farms, feed manufacturers, and veterinary networks enable companies to expand distribution and improve farmer awareness. Many firms are also targeting emerging aquaculture markets in Asia Pacific and Latin America through localized manufacturing and pricing strategies. Additionally, companies are emphasizing sustainable parasite management solutions, including integrated health management programs, to build long-term customer relationships and reinforce their competitive positioning.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Drug class trends
  • 2.2.3 Target parasite trends
  • 2.2.4 Formulation trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising production of aquaculture
    • 3.2.1.2 Surging prevalence of parasitic diseases
    • 3.2.1.3 Development of long-acting formulations and combination therapies
    • 3.2.1.4 Stringent food safety regulations
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Strict approval processes for new veterinary drugs
    • 3.2.2.2 Concerns regarding residual drugs in water bodies
  • 3.2.3 Opportunities
    • 3.2.3.1 Rapid aquaculture growth in emerging markets
    • 3.2.3.2 Integration of smart monitoring systems for parasite detection and targeted drug use
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technological landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Investment landscape
• 3.7 Patent analysis
• 3.8 Pricing analysis
• 3.9 Supply chain analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis
• 3.12 Future market trends

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Class, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Pyrazinoisoquinolones
• 5.3 Benzimidazoles
• 5.4 Macrocyclic lactones
• 5.5 Other drug classes

Chapter 6 Market Estimates and Forecast, By Target Parasite, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Nematodes
• 6.3 Trematodes
• 6.4 Mixed infections
• 6.5 Cestodes

Chapter 7 Market Estimates and Forecast, By Formulation, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Immersion
• 7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 B2B
• 8.3 Veterinary pharmacy
• 8.4 Retail stores
• 8.5 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Norway
  • 9.3.2 Turkey
  • 9.3.3 Germany
  • 9.3.4 UK
  • 9.3.5 France
  • 9.3.6 Spain
  • 9.3.7 Italy
  • 9.3.8 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Indonesia
  • 9.4.4 Vietnam
  • 9.4.5 Japan
  • 9.4.6 South Korea
  • 9.4.7 Australia
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 Egypt
  • 9.6.2 South Africa
  • 9.6.3 Saudi Arabia
  • 9.6.4 UAE

Chapter 10 Company Profiles

• 10.1 API
• 10.2 Aquarium Products India
• 10.3 Aquatic Remedies
• 10.4 Centurion HEALTHCARE
• 10.5 Hikari
• 10.6 KOI PHARMA
• 10.7 Kyoritsu Seiyaku Corporation
• 10.8 Merck & Co., Inc.
• 10.9 NATIONAL FISH PHARMACEUTICALS U.S.A.
• 10.10 Syndel